Clinical Application And Therapeutical Observation Of Biphasic Insulin Aspart 50 On Type 2 Diabetes

Objective To compare the efficacy and safety of biphasic insulin aspart thrice daily (BIAsp50-50-30) with biphasic insulin aspart 30 twice daily (BIAsp30-30) combined with metformin in patients with type 2 diabetes mellitus(T2DM).Methods 28 subjects with T2DM, including 15 men and 13 women, were enrolled. Metformin were given to all patients before insulin therapy. After the run-in period, the subjects were randomized to a 16-week treatment with either BIAsp50-50-30 or BIAsp30-30. 13 cases for BIAsp50- 50-30 group (54.38±6.31 years old), including 6 men and 7 women and 15 cases for BIAsp30-30 group (55.20±6.13 years old), including 9 men and 6 women. The dosages of biphasic insulin aspart 50 or biphasic insulin aspart 30 were adjusted according to the preprandial blood glucose of three meals. Fasting blood glucose (FBG), glycosylated haemoglobin (HbA1c) and self-recorded daily 8-point blood glucose (BG) were measured and com- pared in two groups. The dosages of insulin analogue, hypoglycaemic e- vents and weight were recorded and compared in two groups.Results1. Compared with pretreatment, at the end of 16 weeks treatment, all blood glucose at the eight time point were decreased significantly in both BIAsp50-50-30 group and BIAsp30-30 group (P<0.05). The preprandial and postprandial blood glucose of breskfast and lunch in BIAsp50-50-30 group were higher than those in BIAsp30-30 group (P<0.05).2. Both BIAsp50-50-30 and BIAsp30-30 group reduced FBG and HbA1c. BIAsp50-50-30 reduced more FBG than BIAsp30-30 (P<0.05), but the reduced levels of HbA1c was not significantly different(P>0.05).3. BMI were a little increased in both groups, but there was no sig- nificant difference between two groups (P>0.05). It showed that the dosages in BIAsp50-50-30 was more than that in BIAsp30-30, but there was no significant difference between them (P>0.05).4. BIAsp50-50-30 did not increase the risk of hypoglycemia compared to BIAsp30-30 (P>0.05).Conclusions BIAsp50-50-30 and BIAsp30-30 have similar efficacy and safty profiles in the treatment of type 2 diabetic patients. Both regmin are well tolerated. BIAsp50-50-30 improves postprandial glycemic control, has low hypoglycemia and is more convenient for changing the dose of insulin aspart compared to BIAsp30-30 in patients with T2DM. Biphasic Insulin Aspart trice daily (BIAsp50-50-30) is an ideal insulin therapy of glycemic control in type 2 diabetic patients.